Gastric epithelial expression of trefoil family factor 2 and mucin 6 in normal and Helicobacter pylori-infected subjects by Cheung, HKL et al.
Title Gastric epithelial expression of trefoil family factor 2 and mucin6 in normal and Helicobacter pylori-infected subjects
Author(s) Yang, Y; Xia, HHX; Lam, SK; Wong, WM; Lai, KC; Hu, WHC;Chan, CK; Cheung, HKL; Leung, SY; Yuen, ST; Wong, BCY
Citation
The 8th Medical Research Conference Abstracts, Hong Kong
Medical Journal, Hong Kong, China, 25-26 January 2003, v. 9 n. 1
Supp 1, p. 45
Issued Date 2003
URL http://hdl.handle.net/10722/54115
Rights Creative Commons: Attribution 3.0 Hong Kong License
HKMJ Vol 9 No 1 February 2003 Supplement      45
Gastric epithelial expression of trefoil family factor 2 and mucin 6 in normal and
Helicobacter pylori-infected subjects
Yi Yang1, HHX Xia1, SK Lam1, WM Wong1, KC Lai1, WHC Hu1, CK Chan1, HKL Cheung1, SY Leung2, ST Yuen2 &
BCY Wong1. Departments of Medicine1 and Pathology2, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Introduction: The role of trefoil family factors (TFFs), a group of small secretory peptides, and mucins, the major
components of the mucous viscous gel covering the surface of epithelium, in mucosal defence and healing has been
postulated. H. pylori infection is associated with gastric mucosal inflammation and injury. The aim of this study
was to determine whether H. pylori infection is associated with altered expression of TFF2 and MUC6 at the
different gastric sites.
Method: Gastric biopsy specimens taken from gastric antrum, incisura and body were used for the detection
of H. pylori infection and histological assessment, and the determination of TFF2 and MUC6 expression by
immunohistochemistry.
Results: Of the 76 patients recruited, 27 (35.5%) were positive for H. pylori infection. Chronic gastritis was present
in 26 (96.3%) H. pylori positive patients and 7 (14.3%) H. pylori negative patients (P<0.001). In all 42 (100%)
patients with normal mucosa (i.e. without H. pylori and chronic gastritis), TFF2 and MUC6 were coordinately
expressed in regenerative zone and deep portion of glands of antral mucosa, and only in the regenerative zone of
gastric incisura and body mucosa. However, in patients with H. pylori infection, TFF2 and MUC6 expression was
detected within the foveola of antral mucosa, incisura and body in 59.3%, 44.4% and 11.1%, respectively
(all P<0.05, compared with normal mucosa). Moreover, TFF2 and MUC6 expression was also detected in the
glands of incisura and body mucosa in a proportion (96.3% and 14.8%, respectively) of H. pylori infected patients.
Conclusion: H. pylori infection is associated with extended TFF2 and MUC6 expression in the gastric antral,
incisura and body epithelium, which indicates a protective role of these factors in H. pylori infection.
Role of liver biopsy in the management of liver dysfunction after hematopoietic
stem cell transplantation in a hepatitis B virus prevalent patient population
S.Y. Ma, W.Y. Au, A.K.W. Lie, A.Y.H. Leung, R.H.S. Liang, G.K.K. Lau, Y.L. Kwong.
University Department of Medicine, Queen Mary Hospital, Hong Kong.
Introduction: Derangement of liver-function-tests (LFT) is common after hematopoietic stem-cell-transplantation
(SCT). The role of liver biopsy in such cases has not been defined in hepatitis B virus (HBV) prevalent patients. The
impact of liver biopsy in the management of LFT derangement post-SCT in a HBV-prevalent population was
examined.
Materials and methods. Seventy-five liver biopsies, performed for 323 patients with LFT derangement post-SCT
(263 allogeneic, 60 autologous), were analysed. The HBV carrier rate was 13.6%.
Results. Significantly more LFT derangements and therefore liver biopsies occurred in allogeneic versus
autologous SCT. Prior to biopsy, graft-versus-host disease (GVHD) and HBV reactivation were clinically
diagnosed in 70.6% and 25.3% of cases. A definite histopathologic diagnosis was obtained after biopsy in 53 cases,
with GVHD, HBV-hepatitis and concomitant GVHD/HBV-hepatitis found in 33%, 21% and 8% of cases respectively.
The clinical and histopathologic diagnoses were concordant in 43 cases and discordant in 10 cases. Clinical
management was altered in 6/10 discordant cases, 5 of which were due to HBV or hepatitis C virus (HCV)
reactivation. Twenty-two biopsies showed non-diagnostic histopathologic features. Twenty of these cases were
successfully managed based on clinical diagnoses. The clinical/biochemical features of patients clinically
diagnosed to have GVHD did not differ significantly whether or not they were HBV/HCV carriers. However, liver
biopsies in HBV/HCV carriers resulted in significantly more treatment alterations as compared with non-carriers.
Conclusions. Clinical diagnoses of LFT derangements post-SCT might be adequate for initiation of treatment, but
liver biopsy in HBV/HCV carriers were needed as this might impact on management.
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